2:41 PM
 | 
Jun 13, 2018
 |  BC Extra  |  Company News

Keytruda wins another FDA approval

Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab to treat primary mediastinal...

Read the full 62 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >